Integrated CDMO Solutions For Your Biologics

Advancing a biologic from early development to commercial readiness demands a partner equipped for scale, speed, and scientific rigor. This brochure highlights an integrated CDMO model designed to streamline biologics and bioconjugate programs—from antibody development to complex modalities like ADCs, AOCs, and RDCs.

With multi‑site GMP facilities, flexible bioreactor capacities, and specialized OEB5 environments for potent materials, these services support smooth progression from DNA sequence through clinical and commercial manufacturing. Consolidated platforms for cell-line development, process optimization, conjugation, and drug product fill–finish reduce operational friction while strengthening regulatory readiness. Organizations gain a single, end‑to‑end path that accelerates timelines and enhances quality, positioning teams to move confidently toward IND, NDA, and global launch milestones.

Explore the full brochure to see how integrated capabilities can advance your next biologic.